Tisotumab vedotin can be used, within its marketing authorisation, to treat recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults. Tisotumab vedotin can only be used if the company provides it according to the commercial arrangement.
Tisotumab vedotin must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option. Tisotumab vedotin must be funded in England within 90 days of final publication of this guidance.
There is enough evidence to show that tisotumab vedotin provides benefits and value for money, so it can be used routinely across the NHS in this population.
NICE has produced tools and resources to support the implementation of this guidance.
Usual treatment for recurrent or metastatic cervical cancer that has progressed on or after systemic treatment is single-agent chemotherapy.
Clinical trial evidence shows that tisotumab vedotin increases how long people have before their cancer gets worse, and how long they live, compared with the trial investigator's choice of single-agent chemotherapy.
When considering the condition's severity, and its effect on quality and length of life, the cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, tisotumab vedotin can be used.